Ipsen pledges $10,000 to Red Cross wild fire relief in Alberta

Mississauga, ON – May 23, 2016 — In response to the devastating wild fires in Alberta, Ipsen Biopharmaceuticals Canada Inc. has pledged $10,000 to the Red Cross relief efforts.

“The destruction from the fires in Alberta has been shocking, but the response of generous Canadians and brave relief workers has been an inspiration,” said Lyndal Walker, Country Manager for Ipsen Biopharmaceuticals Canada. “As a health care company, we hope our contribution to the Canadian Red Cross can help in their efforts to alleviate the additional and unforeseen medical costs faced by the people of Fort McMurray.”

Ipsen Biopharmaceuticals Canada, Inc. officially opened its offices in Mississauga in October, 2015.  Since then, Ipsen has been building its presence in Ontario and across Canada by delivering innovative therapies to patients and establishing research collaborations with leading Canadian hospitals and academic centres.

“Our contribution to the Canadian Red Cross is consistent with our larger commitment to the Canadian healthcare system,” said Ms. Walker.  “Our hope is that those impacted by the wildfires in Northern Alberta can return to their homes and begin the process of rebuilding in the near future.”

Ipsen Biopharmaceuticals Canada Inc. is the Canadian operation of Ipsen, a global specialty-driven biotechnology group. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: oncology, neurology and endocrinology.

About Ipsen 

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

For further information:  

Rob Kloppenburg,
Vice President, North America Communications
Tel.: 908-275-6388
E-mail: robert.kloppenburg@ipsen.com